source
- Sellas vaccine shows 9-month overall survival gain in phase 3 AML trialSellas Life Sciences reported results of a phase 3 trial of its peptide vaccine galinpepimut-S (GPS) in patients with acute myeloid leukemia (AML). The study met its primary endpoint, showing a me…
- Helus Pharma’s Phase 3 trial shows strong depression benefit but safety concerns emergeHelus Pharma reported that its deuterated psilocin candidate HLP003 achieved the primary endpoint in a Phase 3 trial for major depressive disorder when added to patients' existing antidepressants.…